Cosmo N.V. (SWX:CMHC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 883.59M -14.2% |
| Revenue (ttm) | 94.79M -43.7% |
| Net Income | -5.86M |
| EPS | -0.36 |
| Shares Out | 17.19M |
| PE Ratio | n/a |
| Forward PE | 844.44 |
| Dividend | 1.97 (3.84%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 30,728 |
| Open | 51.60 |
| Previous Close | 51.90 |
| Day's Range | 51.00 - 53.10 |
| 52-Week Range | 49.00 - 129.40 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | 122.03 (+137.41%) |
| Earnings Date | Apr 19, 2027 |
About Cosmo
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ... [Read more]
Analyst Summary
According to 5 analysts, the average rating for CMHC stock is "Strong Buy." The 12-month stock price target is CHF 122.03, which is an increase of 137.41% from the latest price.
News
Cosmo Transcript: Study update
In phase II, rifamycin TAG met its primary endpoint, with week-six remission of 46.2% vs 14.3% on placebo. Patient-reported usability and the safety profile supported plans to advance the locally acting gel into phase III.
Cosmo Press release: Study update
Cosmo issued a press release on October 19, 2026, disclosing material business information to investors.
Cosmo Slides: Study update
Cosmo has posted slides in relation to its latest quarterly earnings report, which was published on October 19, 2026.
Cosmo Earnings Call Transcript: H1 2026
Delivered 38% year-over-year net revenue growth in H1 2026, driven by strong performance across dermatology, Medtech AI, and CDMO segments, with recurring revenues up 18%. Maintained a debt-free balance sheet with over EUR 200 million in cash, reaffirming full-year guidance and anticipating accelerated growth in H2.
Cosmo Quarterly report: H1 2026
Cosmo has published its H1 2026 quarterly earnings report on July 23, 2026.
Cosmo Earnings release: H1 2026
Cosmo released its H1 2026 earnings on July 23, 2026, summarizing the period's financial results.
Cosmo Slides: H1 2026
Cosmo has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 23, 2026.
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) (“Cosmo”) announced today that it will publish its Half-Year 2026 results on Thursday, 23 July 2026 at 7:00 am CEST.
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) (“Cosmo”) is pleased to make known that its commercial partner Glenmark Specialty S.A (GSSA), a wholly-owned sub...
Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cosmo Pharmaceuticals (CMOPF) to CHF 160 from CHF 130 and keeps a Buy rating on the shares. The firm cites the addition…
Cosmo Earnings Call Transcript: H2 2025
Structural transformation delivered, with 2025 revenue of EUR 104.2 million (85% recurring), EBITDA of EUR 9.5 million, and strong growth in GI Genius and Winlevi. 2026 guidance targets double-digit recurring revenue growth, expanding EBITDA, and a robust cash position.
Cosmo Earnings release: H2 2025
Cosmo released its H2 2025 earnings on March 9, 2026, summarizing the period's financial results.
Cosmo Annual report: H2 2025
Cosmo has published its H2 2025 annual report on March 9, 2026.
Cosmo Slides: H2 2025
Cosmo has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 9, 2026.